OSM treatment on prostate carcinoma cells (DU145) in vitro has been shown to increase the amount of urokinase-type plasminogen activator (u-PA), a serine protease that degrades ECM proteins leading to increased invasion and metastasis in vitro, as well as VEGF measured by means of ELISA (142). The gene discussed is PLAU; the disease is prostate carcinoma.